Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04082884
Recruitment Status : Not yet recruiting
First Posted : September 9, 2019
Last Update Posted : September 9, 2019
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Yale University

Brief Summary:
This prospective, open-label pilot/feasibility study of 10 youth with T1D is to evaluate glycemic and metabolic changes taking place with a very low carbohydrate diet.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Behavioral: VLCD Not Applicable

Detailed Description:

The purpose of this study is to examine changes in sensor glucose levels, basal and bolus insulin doses, and metabolic factors following implementation of a very low carbohydrate diet (VLCD). Sensor-derived time glucose ranges will serve as a surrogate marker of hemoglobin A1c given the short duration of the study. Safety measures of the diet will also be assessed, including daily fasting ketone levels.

The first hypothesis of the study is that use of a VLCD with strict monitoring of ketosis will reduce glycemic variability and increase time in target range, defined as 70-180 mg/dL by reducing the time in the hyperglycemic (>180 mg/dL) and hypoglycemic ranges (<70 mg/dL). Decreased carbohydrate intake will lead to less postprandial hyperglycemia. Lower insulin doses for meals and snacks as a result of decreased carbohydrate intake will lessen postprandial hypoglycemia as well.

Further, changes in glucose and glycerol metabolic fluxes using stable isotopes and indirect calorimetry will be assessed to measure rates of fat oxidation before and after 2 weeks of a VLCD. Arginine infusion will used to assess changes in plasma glucagon responses with the VLCD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes
Estimated Study Start Date : September 15, 2019
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Diet Intervention
Participants will use a very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 50 grams per day or less.
Behavioral: VLCD
A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 50 grams per day or less.




Primary Outcome Measures :
  1. Time in target range [ Time Frame: 2 weeks ]
    The target range is 70 mg/dL - 180 mg/dL based on sensor-derived glucose levels (minutes).


Secondary Outcome Measures :
  1. Time spent > 180 mg/dL [ Time Frame: 2 weeks ]
    The total time spent > 180 mg/dL based on sensor-derived glucose values (minutes).

  2. Time spent > 250 mg/dL based on sensor-derived glucose values [ Time Frame: 2 weeks ]
    The total time spent > 250 mg/dL based on sensor-derived glucose values (minutes).

  3. Time spent < 70 mg/dL based on sensor-derived glucose values [ Time Frame: 2 weeks ]
    The total time spent < 70 mg/dL based on sensor-derived glucose values (minutes).

  4. Time spent < 55 mg/dL based on sensor-derivted glucose values [ Time Frame: 2 weeks ]
    The total time spent < 55 mg/dL based on sensor-derived glucose values (minutes).

  5. Total Daily Insulin Dose [ Time Frame: 2 weeks ]
    The total daily insulin dose will be defined as the average total daily insulin dose will be calculated over 2 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI 19-30 m2 for individuals at least 18 years old or BMI < 95 percentile for individuals less than 18 years old
  • Participants 18 years of age must be able to read and provide written consent
  • Participants under 18 years of age must be able to read and provide written assent
  • Participants are managed using an insulin pump or injections
  • Participant has or is willing to wear a CGM for the duration of the study
  • Participant is willing to complete diet logging procedures stated above

Exclusion Criteria:

  • A1c < 7% or > 10%
  • Recent history of more than 1 of diabetic ketoacidosis (DKA) in the past 6 months
  • Treatment with glucose-lowering drugs other than insulin
  • Unstable psychiatric disorders, including eating disorders (DSM-V criteria)
  • Weight loss medications within the last 6 months
  • Females who are pregnant, lactating or planning to become pregnant in the next 6 months
  • Another medical condition that precludes participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04082884


Contacts
Layout table for location contacts
Contact: Laura Nally, MD 203-785-5831 laura.nally@yale.edu
Contact: Jennifer Finnegan 203-737-7199

Locations
Layout table for location information
United States, Connecticut
Yale-New Haven Hospital Not yet recruiting
New Haven, Connecticut, United States, 06511
Contact: Laura Nally, MD    203-785-5831    laura.nally@yale.edu   
Contact: Jennifer Finnegan    203-737-7199      
Sponsors and Collaborators
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT04082884     History of Changes
Other Study ID Numbers: 2000026189
2K12DK094714-06 ( U.S. NIH Grant/Contract )
First Posted: September 9, 2019    Key Record Dates
Last Update Posted: September 9, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yale University:
very low carbohydrate diet
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases